UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market LLC Warrants to purchase one share of Class A common stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market LLC FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, ...

Exhibit 99.1 GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights 1 Achieved profitability milestone with third quarter adjusted net income of $1.2M Reported third quarter 2024 revenues of $76.6M with 77% year-over-year growth of exome and genome test revenue 2 Expanded third quarter 2024 adjusted gross margins to 64% 2 Raising guidance to deliver between $284M and $290M in FY 2024 revenue GeneDx to host conference call today at 8:30 a.m. ET STAMFORD, Conn., October 29, 2024 — GeneDx ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of WGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Although there are no personal account positions, SOME STOCKS MENTIONED CAN ALREADY BE PART OF THE PORTFOLIOS OF FAMILY AND ASSOCIATES and reti ...

GeneDx Holdings Corp. (NASDAQ:WGS) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies William Bonello - Craig Hallum Mark Massaro - BTIG Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the GeneDx Second Quarter 2024 Ear ...

| --- | --- | --- | |-------|------------------------------------------------------------------------|-------| | | | | | | | | | | One test. Big picture. | | | | Brighter futures. GeneDx (Nasdaq: WGS) 2Q 2024 Earnings Presentation | | 2 Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining ...

Company Performance - GENEDX HOLDINGS reported revenues of $70.51 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 19.72% and showing a year-over-year increase from $48.71 million [2] - The company has surpassed consensus revenue estimates three times in the last four quarters [2] - The stock has increased approximately 1125.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.5% [3] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $60.1 million, and for the current fiscal year, it is -$0.92 on revenues of $240.9 million [5] - The estimate revisions trend for GENEDX HOLDINGS is favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [12] Industry Context - The Medical Services industry, to which GENEDX HOLDINGS belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [13] - Co-Diagnostics, Inc., another company in the same industry, is expected to report revenues of $0.4 million for the quarter ended June 2024, reflecting a 100% increase from the previous year [7]

Title of each class Trading Symbol Name of each exchange on which registered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market LLC Warrants to purchase one share of Class A common stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market LLC GeneDx Holdings Corp. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 x QUART ...

Exhibit 99.1 1 Reported second quarter 2024 revenue from continuing operations of $68.9M with 77% year-over-year growth of exome and genome test revenue 2 Narrowed second quarter 2024 adjusted net loss to $2.7M GeneDx to host conference call today at 4:30 p.m. ET "Our continued organizational focus on execution fueled our strong second quarter results, giving us confidence to raise full year 2024 revenue guidance to between $255-$265 million and reiterate our expectation to reach profitability in the next s ...

Telefonica, S.A. (TEF) : This telecommunications services company has seen the Zacks Consensus Estimate for its current year earnings increasing 9.1% over the last 60 days. GeneDx Holdings Corp. (WGS) : This genomics-related diagnostic and information services company has seen the Zacks Consensus Estimate for its current year earnings 54.5% over the last 60 days. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Here are five stocks added to the Zacks Rank #1 (Strong Buy) List ...

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Let's discuss some of the components of the Momentum Style Score for WGS that show why this company shows promise as a solid momentum pick. Earnings Outlook You can see the current list ...